<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002346</url>
  </required_header>
  <id_info>
    <org_study_id>232B</org_study_id>
    <secondary_id>GS-93-402</secondary_id>
    <nct_id>NCT00002346</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Bis-POM PMEA in HIV-Infected Patients</brief_title>
  <official_title>A Phase I/II Study of Safety, Tolerance, Pharmacokinetics, and Anti-HIV Activity of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA) and Placebo in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To study the safety, tolerance, single and multiple dose pharmacokinetics, and anti-HIV
      activity of bis-POM PMEA ( adefovir dipivoxil ) versus placebo when administered orally on a
      daily basis for 2 weeks to HIV-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive bis-POM PMEA at one of three fixed dose levels or placebo
      daily for 2 weeks. At each dose level, nine patients receive bis-POM PMEA and three patients
      receive placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>36</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Prophylaxis with aerosolized pentamidine, fluconazole, ketoconazole,
             trimethoprim/sulfamethoxazole, or dapsone, provided a stable regimen has been
             maintained for at least 4 weeks prior to study entry.

        Patients must have:

          -  HIV seropositivity.

          -  CD4 count &gt;= 100 cells/mm3.

          -  p24 antigen (immune-complex dissociated) &gt;= 50 pg/ml.

          -  Life expectancy of at least 6 months.

        Prior Medication:

        Allowed:

          -  Prior prophylaxis with aerosolized pentamidine, fluconazole, ketoconazole,
             trimethoprim/sulfamethoxazole, or dapsone.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Active, serious infection (other than HIV infection) requiring parenteral antibiotic
             therapy.

          -  Malignancy other than cutaneous Kaposi's sarcoma.

          -  Clinically significant cardiac disease, including symptoms of ischemia, congestive
             heart failure, or arrhythmia.

          -  Gastrointestinal malabsorption syndrome.

          -  Inability to take oral medication.

        Concurrent Medication:

        Excluded:

          -  Any parenteral antibiotic therapy.

          -  Diuretics.

          -  Amphotericin B.

          -  Didanosine (ddI).

          -  Fluconazole.

          -  Foscarnet.

          -  Ganciclovir.

          -  Interferon-alpha.

          -  Interferon-beta.

          -  Isoniazid.

          -  Aminoglycoside antibiotics.

          -  Ketoconazole (topical allowed).

          -  Itraconazole.

          -  Rifabutin.

          -  Rifampin.

          -  Stavudine (d4T).

          -  Zalcitabine (ddC).

          -  Zidovudine (AZT).

          -  Lamivudine (3TC).

          -  Any investigational agents (except with sponsor approval).

          -  Systemic therapy for Kaposi's sarcoma.

        Patients with the following prior condition are excluded:

        History of lactose intolerance.

        Prior Medication:

        Excluded within 2 weeks prior to study entry:

          -  Any parenteral antibiotic therapy.

          -  Diuretics.

          -  Amphotericin B.

          -  Didanosine (ddI).

          -  Fluconazole.

          -  Foscarnet.

          -  Ganciclovir.

          -  Interferon-alpha.

          -  Interferon-beta.

          -  Isoniazid.

          -  Aminoglycoside antibiotics.

          -  Ketoconazole (topical allowed).

          -  Itraconazole.

          -  Rifabutin.

          -  Rifampin.

          -  Stavudine (d4T).

          -  Zalcitabine (ddC).

          -  Zidovudine (AZT).

          -  Lamivudine (3TC).

          -  Any investigational agents (except with sponsor approval).

        Excluded within 4 weeks prior to study entry:

        Systemic therapy for Kaposi's sarcoma. Active substance abuse (including alcohol) as
        determined by questionnaire or positive drug screen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins Univ</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>James JS. GS 840 (adefovir dipivoxil): broad-spectrum antiviral trial, CD4 count under 100. AIDS Treat News. 1997 Feb 7;(No 264):4-5.</citation>
    <PMID>11364103</PMID>
  </reference>
  <verification_date>March 1995</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Adenine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

